All Articles

IntelliGenome's revolutionary CRISPR-TB diagnostic arrives in South Africa via a key partnership, offering a new, blood-based tool to tackle the TB crisis.

BIOTRONIK Neuro's new AI doesn't just track pain; it anticipates needs, shifting spinal cord stimulation from reactive treatment to proactive, personalized care.

Marpai's $26.4M debt restructuring isn't just about survival. It's a strategic pivot to fuel its AI platform and challenge healthcare administration giants.

A 40-year-old audio giant is challenging high-end norms with a compact speaker platform, betting that integrated design is the future of the industry.

Edge intelligence firm RMX Industries adds former Texas Secretary of State John Scott to its board, a move that telegraphs a serious play for government contracts.

Ottawa extends Babcock Canada’s submarine support contract by six years, a $1.1B deal vital for the current fleet and the transition to a new generation.

With a massive IPO and backing from Agnico Eagle, Cadillac Mines is not just raising capital; it's signaling a major shift in Canada's mining landscape.

VIO's new design isn't just about aesthetics. It's a calculated move to lower franchisee costs, enhance the guest experience, and scale a premium brand.

A key executive move at DLC reveals a deeper strategy: the transformation of open-air shopping centers into the essential physical backbone of our digital lives.

SuanNutra's acquisition of IFF's specialty businesses isn't just a deal; it's a strategic consolidation in the booming clean-label market. Here's why.

Agribusiness giant ADM creates a new COO role for Syngenta's CEO, Jeff Rowe, signaling a strategic acceleration into sustainable agriculture and AI.

Amid record office vacancies, a 54,000 sq-ft lease at the iconic Transamerica Complex signals a strategic wager on the future of premium, flexible work.

After a record-setting boom, Prince Edward Island's construction sector is slowing. This moderation creates a surplus of skilled labor and a critical challenge.

New data reveals a dangerous paradox in Canada's foodservice sector. While sales are growing, soaring costs are erasing profits, stifling investment.

With FDA Fast Track and a key ESMO presentation, Nouscom is de-risking its pioneering cancer interception therapy, NOUS-209, for Lynch Syndrome.

Alkegen's prepackaged bankruptcy isn't a failure, but a calculated maneuver to shed $3.1B in private equity debt and supercharge its role in critical industries.

With promising new data, Nuvation Bio is launching a bold, multi-front clinical strategy for its brain cancer drug. Is this the move that will outmaneuver competitors?

Kamada's new plasma supply agreement is more than just revenue; it's a bold validation of its vertical integration strategy in a competitive global market.

The national 'Click-to-Cancel' rule is dead, but a new regulatory web of state laws and payment processor rules creates a minefield for global startups.